Volume 03 Issue 08-2023
5
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
5-8
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
A
BSTRACT
Drug-induced end-stage renal disease (ESRD) is a significant and potentially preventable cause of renal
failure. This review explores various strategies for the management and prevention of drug-induced ESRD.
Drugs, both prescription and over-the-counter, can lead to nephrotoxicity, acute kidney injury, and chronic
kidney disease, ultimately progressing to ESRD. Understanding the mechanisms of drug-induced kidney
injury is crucial in identifying high-risk medications and patient populations. The review highlights the
importance of drug monitoring, dose adjustments, and renal function assessment to minimize the risk of
drug-induced ESRD. Additionally, it discusses the role of healthcare providers in promoting medication
safety and educating patients about potential renal risks. Furthermore, preventive measures, such as drug
selection algorithms and pharmacogenetic testing, are explored to tailor drug therapies based on
individual patient profiles. This review aims to raise awareness among healthcare professionals and
patients about the importance of vigilant medication management and personalized approaches to
mitigate drug-induced ESRD.
K
EYWORDS
Drug-induced end-stage renal disease, nephrotoxicity, acute kidney injury, chronic kidney disease,
medication management, drug monitoring, dose adjustment, renal function assessment, medication safety,
drug selection algorithms, pharmacogenetic testing, personalized medicine, prevention, healthcare
providers, patient education.
Journal
Website:
http://sciencebring.co
m/index.php/ijasr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Research Article
STRATEGIES FOR MANAGEMENT AND PREVENTION OF
DRUG-INDUCED END-STAGE RENAL DISEASE
Submission Date:
July 28, 2023,
Accepted Date:
Aug 02, 2023,
Published Date:
Aug 07, 2023
Crossref doi:
https://doi.org/10.37547/ijasr-03-08-02
Gagan Mittal
Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut, U.P.,
India
Volume 03 Issue 08-2023
6
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
5-8
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
I
NTRODUCTION
Drug-induced end-stage renal disease (ESRD) is a
growing concern in clinical practice, posing a
significant challenge to healthcare providers and
patients alike. The kidneys play a vital role in drug
metabolism and excretion, making them
susceptible to drug-related injury. Drug-induced
nephrotoxicity, acute kidney injury (AKI), and
chronic kidney disease (CKD) can all contribute to
the progression of ESRD, resulting in substantial
morbidity and mortality. Addressing the
management and prevention of drug-induced
ESRD is of utmost importance to optimize patient
outcomes and reduce the burden on healthcare
systems.
Various factors contribute to drug-induced renal
injury, including drug-specific properties, patient
characteristics,
drug
interactions,
and
comorbidities. Identifying high-risk medications
and patient populations is essential in
formulating effective strategies to minimize the
occurrence and severity of drug-induced ESRD.
This review aims to explore current approaches
for the management and prevention of drug-
induced ESRD, emphasizing the importance of
medication management, drug monitoring, dose
adjustments, renal function assessment, and
personalized medicine in mitigating this renal
risk.
M
ETHOD
To conduct this comprehensive review, a
systematic search of scientific literature was
performed. A thorough examination of electronic
databases, such as PubMed, Scopus, and Web of
Science, was undertaken to identify relevant
studies, articles, and reviews related to drug-
induced ESRD and its management and
prevention. The search was not limited by
language and covered literature up to the present
date.
The selected literature encompassed studies
investigating drug-induced nephrotoxicity, AKI,
CKD, and ESRD. Both experimental and clinical
studies
were
included
to
provide
a
comprehensive
understanding
of
the
mechanisms involved in drug-induced renal
injury. Additionally, publications addressing
medication management, drug monitoring, dose
adjustments, and renal function assessment in the
context of drug-induced ESRD were incorporated.
The review also considered articles related to
personalized medicine, pharmacogenetic testing,
and individualized drug selection algorithms to
tailor drug therapies based on patient-specific
factors and genetic profiles. Preventive measures
and best practices in medication safety and
patient education regarding renal risks were also
explored.
The findings from the selected literature were
analyzed, synthesized, and organized to present a
comprehensive overview of the strategies for
managing and preventing drug-induced ESRD.
The review aims to provide valuable insights for
healthcare
providers,
researchers,
and
Volume 03 Issue 08-2023
7
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
5-8
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
policymakers, emphasizing the significance of
vigilant
medication
management
and
personalized approaches to enhance renal safety
and improve patient outcomes.
R
ESULTS
The comprehensive review on strategies for the
management and prevention of drug-induced
end-stage renal disease (ESRD) revealed several
important findings. Drug-induced nephrotoxicity,
acute kidney injury (AKI), and chronic kidney
disease (CKD) are significant contributors to the
development of end-stage renal disease, placing a
substantial burden on patients and healthcare
systems. Various medications, both prescription
and over-the-counter, have been associated with
renal injury, highlighting the importance of
vigilant medication management.
D
ISCUSSION
The review highlighted the critical role of drug
monitoring and renal function assessment in
identifying early signs of drug-induced renal
injury. Regular monitoring of renal function
allows for timely detection of changes in kidney
function, prompting appropriate interventions,
such as dose adjustments or discontinuation of
nephrotoxic medications. Healthcare providers
play a crucial role in ensuring that medications
are prescribed at appropriate doses, especially in
patients with impaired renal function.
Moreover, personalized medicine emerged as a
promising approach to prevent drug-induced
ESRD. Pharmacogenetic testing can help identify
patients with genetic variations that may
predispose them to adverse drug reactions,
including renal toxicity. Tailoring drug therapies
based on individual patient profiles can reduce
the risk of drug-induced renal injury and improve
treatment outcomes.
The review also emphasized the importance of
medication safety and patient education.
Healthcare providers should educate patients
about the potential renal risks associated with
certain medications and the importance of
adhering to prescribed doses. Empowering
patients with knowledge about their medications
and their impact on renal health can lead to
improved medication adherence and early
recognition of adverse effects.
Preventive measures, such as drug selection
algorithms, can guide healthcare providers in
choosing medications with a lower risk of renal
toxicity when treating patients with pre-existing
kidney conditions or those at higher risk for drug-
induced renal injury.
C
ONCLUSION
In conclusion, drug-induced end-stage renal
disease is a significant clinical concern that
requires a multifaceted approach for effective
management and prevention. Strategies such as
drug monitoring, dose adjustments, renal
function assessment, personalized medicine, and
medication safety education can collectively
reduce the incidence and severity of drug-
induced ESRD. By implementing these strategies,
healthcare providers can optimize patient care
Volume 03 Issue 08-2023
8
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
5-8
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
and improve renal outcomes, ultimately
contributing to better overall patient health and
well-being. Additionally, further research in this
area is warranted to identify novel therapeutic
targets and refine existing strategies to combat
drug-induced renal injury and its progression to
end-stage renal disease.
R
EFERENCES
1.
Kellum JA, Levin N, Bouman C, Lameire N. Curr
Opin Crit Care, 2002;8:509-514.
2.
Mehta RL, Chertow GM. J Am Soc Nephrol,
2003; 14:2178-2187.
3.
Whelton A. Am J Med, 1999; 106:13S-24S.
4.
Han WK, Bailly V, Abichandani R. Kidney
Int, 2002; 62:237-244.
5.
Baliga R, Ueda N, Walker PD, Shah SV. Drug
Metab Rev, 1999; 31:971-997.
6.
Swan SK. Semin Nephrol, 1997; 17:27-33.
7.
Rudnick MR, Berns JS, Cohen RM, Goldfarb
S. Semin Nephrol, 1997; 17:15-26.
8.
Solomon R.. Kidney Int, 1998;53:230-242.
9.
9. Murphy SW, Barrett BJ, Parfrey PS. J Am
Soc Nephrol, 2000; 11:177-182.
10.
Waybill MM, Waybill PN. JV asc Intervent
Radiol, 2001; 12:3- 9.
11.
Kintzel PE. Drug Saf, 2001; 24:19-38.
